Burden of Nonadvanced systemic mastocytosis
1 evidence topic · 3 sources
Summary
In the Danish register study, all nonadvanced SM was classified as ISM; prevalence on January 1, 2022 was 9.36 per 100,000. In a U.S. survey of people with SM, 54% reduced work hours and 64% avoided leaving home because of symptoms. These survey estimates are not specific to nonadvanced disease. A separate matched-control study reported mean post-index medical costs of $24,588 for nonadvanced SM versus $14,419 for controls.